蔡嘉, 黄红武, 彭丙枞, 唐嘉锶, 谢培康, 陈湘钰, 贺冬秀. 线粒体靶向纳米制剂在癌症免疫治疗中的研究进展J. 药学学报, 2026, 61(2): 426-440. DOI: 10.16438/j.0513-4870.2025-0199
引用本文: 蔡嘉, 黄红武, 彭丙枞, 唐嘉锶, 谢培康, 陈湘钰, 贺冬秀. 线粒体靶向纳米制剂在癌症免疫治疗中的研究进展J. 药学学报, 2026, 61(2): 426-440. DOI: 10.16438/j.0513-4870.2025-0199
CAI Jia, HUANG Hong-wu, PENG Bing-cong, TANG Jia-si, XIE Pei-kang, CHEN Xiang-yu, HE Dong-xiu. Recent advancements in mitochondria-targeted nanoformulations for cancer immunotherapyJ. Acta Pharmaceutica Sinica, 2026, 61(2): 426-440. DOI: 10.16438/j.0513-4870.2025-0199
Citation: CAI Jia, HUANG Hong-wu, PENG Bing-cong, TANG Jia-si, XIE Pei-kang, CHEN Xiang-yu, HE Dong-xiu. Recent advancements in mitochondria-targeted nanoformulations for cancer immunotherapyJ. Acta Pharmaceutica Sinica, 2026, 61(2): 426-440. DOI: 10.16438/j.0513-4870.2025-0199

线粒体靶向纳米制剂在癌症免疫治疗中的研究进展

Recent advancements in mitochondria-targeted nanoformulations for cancer immunotherapy

  • 摘要: 线粒体通过直接参与免疫细胞的活化、增殖和分化, 调控多条免疫相关信号通路, 并借助其动力学和代谢变化影响肿瘤浸润免疫细胞的功能, 从而在抗癌免疫反应中发挥重要调控作用。靶向线粒体的免疫治疗是一种新兴的癌症治疗策略。构建的线粒体靶向免疫制剂通过诱导肿瘤免疫原性细胞死亡、调节线粒体动力学和代谢、激活免疫信号通路等多种免疫策略, 显著改善抗癌功效。本文聚焦于癌症免疫治疗领域, 介绍了线粒体与肿瘤免疫的关系, 并总结了近5年来靶向线粒体纳米制剂的设计、开发及其在癌症免疫治疗中的应用进展。最后讨论线粒体靶向纳米制剂在抗癌免疫治疗方面所面临的挑战与前景, 以期为开发用于癌症免疫治疗的新型线粒体靶向制剂提供依据。

     

    Abstract: Mitochondria plays an important regulatory role in the anticancer immune response by directly participating in the activation, proliferation and differentiation of immune cells, regulating multiple immune signaling pathways and affecting the activation and function of tumor-infiltrating immune cells with the help of the change of mitochondrial dynamics and metabolic. Mitochondria-targeted immunotherapy is an emerging cancer treatment strategy. The constructed mitochondrial targeted nanoformulation significantly improves the anti-cancer efficacy by inducing immunogenic cell death, regulating mitochondrial dynamics and metabolism, activating immune signaling pathways and other immune strategies. This review focuses on the field of cancer immunotherapy, introduces the relationship between mitochondria and tumor immunity, and summarizes the design of mitochondria-targeted nanomaterials in the past five years. Finally, the challenges and prospects of mitochondria-targeted nanoformulations in anti-cancer immunotherapy are discussed in this paper, which offers support for the development of novel mitochondria-targeted agents for cancer immunotherapy in the future.

     

/

返回文章
返回